

## **Supplementary Methods**

### **Flow cytometric monocyte HLA-DR expression analysis**

Peripheral blood samples were collected in EDTA-containing tubes which were kept on ice and rapidly routed to the laboratory. Whole blood (50  $\mu$ l) was stained with 20  $\mu$ l of QuantiBrite anti-HLA-DR/Monocyte mixture (QuantiBrite anti-HLA-DR PE (clone L243)/Anti-monocytes (CD14) PerCP-Cy5.5 (clone M $\Phi$ P9), Becton Dickinson, San José, CA) at room temperature for 30 min in the dark. Samples were then lysed using the FACS Lysing solution (Becton Dickinson) for 15 min. After a washing step, cells were analyzed with BD FACSCanto-II flow cytometer and FACSDiva software version 8 (BD Biosciences, San José, CA). Monocytes were first gated out from other cells on the basis of CD14 expression and mHLA-DR expression was then measured on their surface (mono-parametric histogram) as median of fluorescence intensity related to the entire monocyte population (as recommended by manufacturer). These results were then transformed in AB/C (number of antibodies fixed per cell) thanks to calibrated PE-beads (BD QuantiBrite-PE Beads, Becton Dickinson).

### **Statistical analysis**

Primary objective was analyzed using a non-supervised analysis: hierarchical ascendant clustering (HAC) [13]. The goal of this method is to cluster the entire analyzed population. This uses an iterative way to group observations in clusters, by a distance and an aggregation method. The end of iterations results in a unique cluster made up of the whole observations. We can illustrate results with a dendrogram.

HAC needs two parameters a priori:

- A distance: in this study the Euclidian distance

- An aggregation method: in this study the Ward's linkage method [10]

HAC results in all the possible clusters with the previously parameters, and defined variables. In our case, variables are the following: Leucocytes G/L, Lymphocytes G/L, total CD3<sup>+</sup> T cells G/L, total CD4<sup>+</sup> T cells G/L, total CD8<sup>+</sup> T cells G/L, total CD3<sup>+</sup> T cells %, total CD4<sup>+</sup> T cells %, total CD8<sup>+</sup> T cells %, CD4<sup>+</sup>/CD8<sup>+</sup>, CD3-CD56<sup>+</sup> %, naive CD4<sup>+</sup> T cells %, central memory CD4<sup>+</sup> T cells %, effector CD4<sup>+</sup> T cells %, naive CD8<sup>+</sup> T cells %, central memory CD8<sup>+</sup> T cells %, effector CD8<sup>+</sup> T cells %, CD8 CDRA<sup>+</sup> CCR7 %, regulatory T cells %, CD4<sup>-</sup>CD8<sup>-</sup>/CD3<sup>+</sup> %, CD57<sup>+</sup>/CD4<sup>+</sup> %, CD57<sup>+</sup>/CD8<sup>+</sup> %, CD57 %, CD56<sup>+</sup>/CD4<sup>+</sup> %, CD56<sup>+</sup>/CD8<sup>+</sup> %, HLA-DR<sup>+</sup>/CD4<sup>+</sup> %, HLA-DR<sup>+</sup>/CD8<sup>+</sup> %, CD25<sup>+</sup>/CD4<sup>+</sup> %, CD25<sup>+</sup>/CD8<sup>+</sup> %, total B cells G/L total B cells %, transitional B cells %, naive B cells %, natural memory B cells %, post germinal memory B cells %, plasmablasts %, post germinal switched memory B cells %, total NK cells G/L, total NK cells %, cytotoxic NK cells %, inflammatory NK cells %, immunomodulatory NK cells %, CD16<sup>-</sup> CD56<sup>-</sup> %, total monocytes %, non-conventional monocytes %. We added age, which might be a variation factor for some of the lymphocyte subpopulations [12].

HAC was implemented using Stata 15 (StataCorp, College Station, TX, USA), with the command cluster 'wardslinkage'. The optimal number of clusters was choosing using selection criterions of Calinski-Harabasz and Duda-Hart, with the following command: 'cluster stop'.

A biological meaning of the clusters was analyzed by screening the values of every parameter, between all clusters. ANOVA F-test was conducted for parameters with a Gaussian distribution, and a non-parametric Mann-Whitney test was run for other distributions. For significant results, a specific cluster by cluster tests were conducted to identify the significantly different cluster. This was conducted using Student tests for


Gaussian distributions, Wilcoxon tests for others. Only high significant results were discussed, to take part of the risk of error inflation, due to multiplicity of tests.

367 SARS-CoV-infected hospitalized patients in  
Grenoble University Hospital between March  
18<sup>th</sup> and September 20<sup>th</sup> 2020

146 patients recruited in Grenoble University Hospital  
127 in the retrospective BioMarCoViD study (non-opposition)  
19 in the prospective AcNT-COVID19 study (written consent)

Incomplete biological explorations for 21 patients

125 patients analyzed :  
106 in the retrospective BioMarCoViD study  
19 in the prospective AcNT-COVID19 study



**S1 Table.** Classification of severity.

<b>Characteristics</b>	<b>Class of severity</b>
no O <sub>2</sub> requirement	mild disease
O <sub>2</sub> ≤ 2L/min	mild disease
O <sub>2</sub> > 2L/min	severe disease
ICU admission	severe disease
LTE	severe disease
decease	severe disease

LTE : Limitation of Therapeutic Effort

**S2 Table.** Panel of four antibody combinations used in the study.

<b>Fluoro- chrome Tube</b>	<b>FITC</b>	<b>PE</b>	<b>PerCP or PerCP- Cy5.5</b>	<b>PE-Cy7</b>	<b>APC</b>	<b>APC-Cy7 or APC- H7</b>	<b>V450</b>	<b>V500</b>
1	CD3	CD56 and CD16	CD45	CD4	CD19	CD8	HLA-DR	x
2	CD57	CD8	CD45	CD3	CD45RA	x	CCR7	x
3	IgD	CD10	CD38	CD27	IgM	CD19	x	x
4	CD3	CD127	CD45	CD56	CD25	CD16	CD7	CD45

**S3 Table.** Characteristics of antibodies.

<b>CD</b>	<b>Fluorochrome</b>	<b>Clone</b>	<b>Isotype</b>	<b>Supplier</b>	<b>Catalogue N°</b>
CD3	FITC	SK7	Ms IgG1, κ	BD Biosciences	644611
CD4	PE-Cy7	SK3	Ms IgG1, κ	BD Biosciences	644611
CD8	APC-H7	SK1	Ms IgG1, κ	BD Biosciences	644611
CD19	APC	SJ25C1	Ms IgG1, κ	BD Biosciences	644611
CD16	PE	B73.1	Ms IgG1, κ	BD Biosciences	644611
CD56	PE	NCAM16.2	Ms IgG2b, κ	BD Biosciences	644611
CD45	PerCP	2D1	Ms IgG1, κ	BD Biosciences	644611
HLA-DR	V450	L243	Ms IgG2a, κ	BD Biosciences	655874
CD8	PE	B9.11	Ms IgG1	Beckman Coulter	A07757
CD4	PerCP-Cy5.5	SK3	Ms IgG1, κ	BD Biosciences	332772
CD3	PE-Cy7	UCHT1	Ms IgG1	Beckman Coulter	737657
CD45RA	APC	HI100	Ms IgG2b, κ	BD Biosciences	550855
CD197	VB421	150503	Ms IgG2a	BD Biosciences	562555
IgD	FITC	polyclonal	rabbit anti-human	Agilent technologies	F018901
CD10	PE	HI10a	Ms IgG1, κ	BD Biosciences	332776
CD38	PerCP-Cy5.5	HIT2	Ms IgG1, κ	BD Biosciences	551400
CD27	PE-Cy7	1A4CD27	Ms IgG1	Beckman Coulter	B49205
IgM	APC	G20-127	Ms IgG1, κ	BD Biosciences	551062
CD19	APC-H7	SJ25C1	Ms IgG1, κ	BD Biosciences	641395
CD127	PE	HIL-7R-M21	Ms IgG1, κ	BD Biosciences	557938
CD56	PE-Cy7	N901 (NKH-1)	Ms IgG1	BD Biosciences	A21692
CD25	APC	2A3	Ms IgG1, κ	BD Biosciences	340907
CD16	APC-H7	3G8	Ms IgG1, κ	BD Biosciences	560195
CD7	V450	T701	Ms IgG1, κ	BD Biosciences	642916
CD45	V500	HI30	Ms IgG1, κ	BD Biosciences	560777



**S4 Table.** Cell subsets and corresponding immunophenotypes.

<b>Cell subset</b>	<b>Immunophenotype</b>
<b>T-cell subsets</b>	
Total CD4 <sup>+</sup> T cells	CD3 <sup>+</sup> CD4 <sup>+</sup>
Naive CD4 <sup>+</sup> T cells	CD45RA <sup>+</sup> CCR7 <sup>-</sup>
Central memory CD4 <sup>+</sup> T cells	CD45RA <sup>-</sup> CCR7 <sup>-</sup>
Effector CD4 <sup>+</sup> T cells	CD45RA <sup>+</sup> CCR7 <sup>-</sup>
Regulatory T cells	CD4 <sup>+</sup> CD127 <sup>low</sup> CD25 <sup>high</sup>
Total CD8 <sup>+</sup> T cells	CD3 <sup>+</sup> CD8 <sup>+</sup>
Naive CD8 <sup>+</sup> T cells	CD45RA <sup>+</sup> CCR7 <sup>-</sup>
Central memory CD8 <sup>+</sup> T cells	CD45RA <sup>-</sup> CCR7 <sup>-</sup>
Effector CD8 <sup>+</sup> T cells	CD45RA <sup>+/-</sup> CCR7 <sup>-</sup>
<b>B-cell subsets</b>	
Total B cells	CD19 <sup>+</sup>
Transitional B cells	IgD <sup>+</sup> CD27 <sup>-</sup> CD10 <sup>+</sup> CD38 <sup>high</sup>
Naive B cells	IgD <sup>+</sup> CD27 <sup>-</sup> CD10 <sup>-</sup> CD38 <sup>low</sup>
Natural memory B cells	IgD <sup>+</sup> CD27 <sup>+</sup>
Post germinal memory B cells	IgD <sup>-</sup> CD27 <sup>+</sup> CD38 <sup>low</sup>
Plasmablasts	IgD <sup>-</sup> CD27 <sup>high</sup> CD38 <sup>high</sup>
<b>NK cells</b>	
Total NK cells	CD56 <sup>+</sup> or CD16 <sup>+</sup> and CD3 <sup>-</sup>
Cytotoxic NK cells	CD56 <sup>+</sup> CD16 <sup>+</sup> CD3 <sup>-</sup>
Immunomodulatory NK cells	CD56 <sup>-</sup> CD16 <sup>+</sup> CD3 <sup>-</sup>
Inflammatory NK cells	CD56 <sup>+</sup> CD16 <sup>-</sup> CD3 <sup>-</sup>
<b>Monocytes</b>	
Total monocytes	CD45 <sup>high</sup> SSC <sup>intermediate</sup>
Non-conventional monocytes	CD16 <sup>+</sup>

**S5 Table.** Overall comparison of cellular subpopulations between the clusters.

	<b>Cluster 1</b>	<b>Cluster 2</b>	<b>Cluster 3</b>	<b>Cluster 4</b>	<b>Cluster 5</b>	<b>p-value</b>
Leucocytes, G/L	5.7 [3.7;8.2]	6.3 [4.6;10.3]	8.5 [5.9;10.8]	5.4 [4.1;7.8]	6.1 [3.9;7.1]	0.089 <sup>1</sup>
Lymphocytes, G/L	0.9 [0.7;1.5]	0.9 [0.6;1.4]	0.6 [0.4;1.2]	1.2 [0.7;1.5]	0.8 [0.6;1.3]	0.27 <sup>1</sup>
Lymphocytes, %	18 [12;28]	14 [7;23]	7 [6;15]	19 [11;24]	17 [10;23]	0.018 <sup>1</sup>
<b>T-cell subsets</b>						
Total CD3 <sup>+</sup> T cells, G/L	0.7 [0.5;1.1]	0.6 [0.4;0.9]	0.4 [0.3;0.7]	0.8 [0.6;1]	0.6 [0.4;0.9]	0.11 <sup>1</sup>
Total CD4 <sup>+</sup> T cells, G/L	0.5 [0.3;0.8]	0.4 [0.2;0.6]	0.3 [0.2;0.5]	0.4 [0.2;0.5]	0.4 [0.3;0.6]	0.049 <sup>1</sup>
Total CD8 <sup>+</sup> T cells, G/L	0.2 [0.1;0.3]	0.1 [0.1;0.2]	0.1 [0.1;0.2]	0.4 [0.2;0.5]	0.2 [0.1;0.2]	0.001 <sup>1</sup>
Total CD3 <sup>+</sup> T cells, %	72 [67;81]	63 [55;71]	67 [59;74]	77 [74;82]	74 [66;83]	p<0.001 <sup>1</sup>
Total CD4 <sup>+</sup> T cells, %	52 (10)	43 (10)	43 (12)	32 (9)	48 (10)	p<0.001 <sup>2</sup>
Total CD8 <sup>+</sup> T cells, %	17 (8)	17 (7)	19 (7)	38 (14)	22 (8)	p<0.001 <sup>2</sup>
CD4 <sup>+</sup> /CD8 <sup>+</sup>	3.1 [2;4.9]	2.8 [1.7;3.5]	2 [1.5;3.4]	0.9 [0.8;1.5]	1.9 [1.6;3.6]	p<0.001 <sup>1</sup>
Naive CD4 <sup>+</sup> T cells, %	53 (16)	36 (12)	47 (18)	25 (10)	51 (13)	p<0.001 <sup>2</sup>
Central memory CD4 <sup>+</sup> T cells, %	34 (12)	49 (11)	32 (8)	36 (11)	28 (11)	p<0.001 <sup>2</sup>
Effector CD4 <sup>+</sup> T cells, %	12 [8;16]	14 [11;18]	15 [12;18]	35 [32;42]	19 [12;26]	p<0.001 <sup>1</sup>
Naive CD8 <sup>+</sup> T cells, %	46 [32;55]	21 [15;27]	22 [15;33]	7 [5;11]	8 [6;14]	p<0.001 <sup>1</sup>
Central memory CD8 <sup>+</sup> T cells, %	11 [7;19]	15 [10;18]	6 [5;12]	5 [3;8]	4 [3;7]	p<0.001 <sup>1</sup>
Effector CD8 <sup>+</sup> T cells, %	44 [36;50]	64 [57;70]	71 [58;75]	87 [81;91]	85 [82;90]	p<0.001 <sup>1</sup>
Regulatory T cells, %	7 [5;8]	9 [7;10]	8 [6;10]	7 [5;9]	7 [6;8]	0.049 <sup>1</sup>
CD4 <sup>+</sup> CD8 <sup>+</sup> /CD3 <sup>+</sup> , %	2 [2;4]	3 [2;5]	2 [2;3]	4 [2;4]	2 [1;6]	0.463 <sup>1</sup>
<b>T-cell activation markers</b>						
HLA-DR <sup>+</sup> /CD4 <sup>+</sup> , %	6 [5;8]	9 [7;11]	14 [9;19]	14 [12;18]	13 [8;18]	p<0.001 <sup>1</sup>
HLA-DR <sup>+</sup> /CD8 <sup>+</sup> , %	18 [14;27]	31 [26;40]	55 [33;62]	37 [24;50]	53 [31;63]	p<0.001 <sup>1</sup>
<b>T-cell senescence markers</b>						
CD57 <sup>+</sup> /CD4 <sup>+</sup> , %	1 [1;2]	1 [1;3]	2 [1;4]	16 [11;23]	6 [1;9]	p<0.001 <sup>1</sup>
CD57 <sup>+</sup> /CD8 <sup>+</sup> , %	14 [10;19]	32 [26;44]	18 [13;23]	50 [47;54]	44 [31;54]	p<0.001 <sup>1</sup>
<b>B-cell subsets</b>						
Total B cells, G/L	0.1 [0.1;0.2]	0.1 [0.1;0.2]	0.1 [0.1;0.2]	0.1 [0.0;0.1]	0.1 [0.0;0.1]	0.049 <sup>1</sup>
Total B cells, %	12 [8;17]	17 [12;23]	17 [10;24]	10 [7;11]	9 [6;12]	0.001 <sup>1</sup>
Transitional B cells, %	4 [2;6]	4 [2;6]	1 [1;4]	5 [2;6]	1 [1;3]	p<0.001 <sup>1</sup>
Naive B cells, %	58 (16)	55 (14)	31 (17)	53 (12)	43 (22)	p<0.001 <sup>2</sup>
Natural memory B cells, %	8 [4;12]	8 [4;10]	6 [3;21]	9 [5;14]	6 [4;9]	0.794 <sup>1</sup>
Post germinal memory B cells, %	12 [8;18]	14 [9;18]	9 [7;16]	13 [9;19]	15 [11;35]	0.056 <sup>1</sup>
Plasmablasts, %	4 [2;11]	7 [3;12]	29 [23;42]	5 [3;10]	6 [3;14]	p<0.001 <sup>1</sup>
<b>NK-cell subsets</b>						
Total NK cells, G/L	0.1 [0.1;0.2]	0.1 [0.1;0.2]	0.1 [0.0;0.1]	0.1 [0.1;0.2]	0.1 [0.1;0.2]	0.57 <sup>1</sup>
Total NK cells, %	12 [7;18]	15 [9;25]	14 [8;21]	12 [10;18]	14 [6;21]	0.595 <sup>1</sup>
Cytotoxic NK cells, %	89 [85;94]	89 [79;92]	90 [88;94]	92 [85;96]	92 [90;94]	0.105 <sup>1</sup>
Inflammatory NK cells, %	2 [1;4]	3 [1;7]	2 [1;4]	2 [1;3]	2 [2;5]	0.661 <sup>1</sup>
Immunomodulatory NK cells, %	5 [4;9]	6 [4;13]	4 [3;8]	4 [3;7]	4 [2;6]	0.206 <sup>1</sup>
<b>Monocytes</b>						
Total monocytes, %	8.0 (3.6)	7.5 (3.3)	7.1 (2.7)	7.0 (3.0)	7.2 (3.3)	0.779 <sup>2</sup>
Non-conventional monocytes, %	12 [7;19]	11 [7;14]	5 [3;12]	13 [10;17]	14 [10;26]	0.003 <sup>1</sup>
mHLA-DR, AB/C <sup>3</sup>	42044 (17038)	25218 (17485)	21009 (9786)	44608 (20302)	47150 (19101)	0.004 <sup>2</sup>
<b>Other</b>						
Age	56 [44.6;72.1]	70 [56.6;75.6]	71 [62.3;80.6]	72 [64.1;82.5]	79 [70.8;89.3]	p<0.001 <sup>1</sup>

<sup>1</sup> p-value from Kruskal Wallis test due to non-normality distribution; median [IQR]<sup>2</sup> p-value from F-test Anova due to normality distribution; mean (SD)<sup>3</sup> number of antibodies fixed per cell

**S6 Table.** Major characteristics of the five clusters of patients.

	<b>Cluster 1</b>	<b>Cluster 2</b>	<b>Cluster 3</b>	<b>Cluster 4</b>	<b>Cluster 5</b>
<b>Age (mean)<sup>1</sup></b>	56.4	66.6	70.1	72.5	79
<b>Lymphocytes G/L</b>	low	low	low	low	low
<b>CD8<sup>+</sup> T cells</b>	low	very low	very low	normal	low
<b>Effector CD8<sup>+</sup> T cells</b>	high	very high	very high	extremely high	extremely high
<b>Effector CD4<sup>+</sup> T cells</b>	normal	normal	normal	high	normal
<b>CD4<sup>+</sup> and CD8<sup>+</sup> activation</b>	low activation	high	very high	very high	very high
<b>CD8<sup>+</sup> senescence</b>	low senescence	high	low senescence	very high	very high
<b>CD4<sup>+</sup> senescence</b>	low senescence	low senescence	low senescence	very high	high
<b>Plasmablasts</b>	normal/high	high	extremely high	high	high
<b>mHLA-DR</b>	normal	normal/low	normal/low	normal	normal
<b>Mortality<sup>2</sup></b>	0	17.4	9.5	11.1	26.1

<sup>1</sup> p<0.0001 cluster 1 against others; cluster 5 against others

<sup>2</sup> p=0.005 cluster 1 against others; p= 0.006 clusters 2 and 5 against others